💊 İlaçlar A-Z 🧬 Hedefler 🛠 Araçlar 📚 Rehberler
Tüm İlaçlar İlaç Sınıfları Terapötik Alanlar Yan Etkiler
Rehberler Sözlük Zaman Çizelgesi
Karşılaştırmalar İlaç Yolculukları İlaç Aileleri
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Edoxaban Tosylate

CHEMBL2105682 Phase 4 Onaylandı Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
720.3 g/mol
LogP
—
Phase
4

A tosylate salt form of edoxaban used to prevent strokes in atrial fibrillation and to treat venous thromboembolism. Like the parent compound, it works by directly blocking factor Xa to prevent clot formation.

Moleküler Ağırlık

720,3000 g/mol

TPSA

228,00 Ų

Terapötik Alanlar

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Stroke Deep Vein Thrombosis / Pulmonary Embolism Breast Cancer Heart Failure Atrial Fibrillation Prostate Cancer Colorectal Cancer

Etki Mekanizması

Direct, selective inhibitor of Factor Xa preventing thrombin generation and clot formation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Direct, selective inhibitor of Factor Xa preventing thrombin generation and clot formation.

2D Yapı

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1.Cc1ccc(S(=O)(=O)O)cc1

                

                

                
                

                    
InChI

                    
InChI=1S/C24H30ClN7O4S.C7H8O3S/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23;1-6-2-4-7(5-3-6)11(8,9)10/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34);2-5H,1H3,(H,8,9,10)/t13-,15-,17+;/m0./s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C31H38ClN7O7S2

                    

                    
                    

                        
HBD / HBA

                        
4 / 11

                    

                    
                    

                        
Döndürülebilir Bağlar

                        
6

                    

                    
                    
                    

                        
Ağır Atomlar

                        
48

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Sıkça Sorulan Sorular

                

                    
                    

                        
                        

                            
A tosylate salt form of edoxaban used to prevent strokes in atrial fibrillation and to treat venous thromboembolism. Like the parent compound, it works by directly blocking factor Xa to prevent clot formation.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Direct, selective inhibitor of Factor Xa preventing thrombin generation and clot formation.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Edoxaban Tosylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2105682.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 44610678.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Tıbbi Sorumluluk Reddi

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.